20 October 2015: advertising of a prescription-only medicine to the public
Published 25 November 2015
© Crown copyright 2015
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-october-2015/20-october-2015-advertising-of-a-prescription-only-medicine-to-the-public
Fresenius Kabi wrote to MHRA to express concerns that their product, Intralipid was being promoted for use in fertility treatment, an indication that it is not licensed to treat.
MHRA reviewed the websites of a number of clinics and provided advice on compliance with the legislation on advertising medicines.